The cooperation agreement was signed on June 6 in St. Petersburg within the framework of SPIEF by the head of the innovative pharmaceuticals department, Director of the Institute of Translational Medicine and Biotechnology of Sechenov University Vadim Tarasov and the President of the «AKRIKHIN» Denis Chetverikov.

The main goal of the partnership is to create innovative drugs of the GLP-1 and SGLT-2 classes, which are the basis of modern approaches to the treatment of type 2 diabetes, neuropathy and other metabolic disorders.

GLP-1 agonists are a modern class of glucose-lowering drugs that can provide reliable glycemic control, weight loss, reduce the risks of cardiovascular complications and renal dysfunction; they are widely used for the treatment of metabolic disorders in Europe and the USA. Currently, sales of GLP-1 account for 55% of all global sales of drugs for the treatment of type 2 diabetes. Bloomberg predicts sales of GLP-1 agonists will reach $800 billion annually by 2030.

And the entry to the market of domestic SGLT-2 inhibitors, which, due to a fundamentally new mechanism of action, significantly improve control of blood glucose levels, have shown high effectiveness in chronic heart failure and chronic kidney disease, makes it possible for patients to receive treatment at the level of world standards.

Denis Chetverikov, President of «AKRIKHIN»: «Today our company is taking a significant step towards improving the health and quality of life of our compatriots», said Denis Chetverikov, President of the company. - The signing of an agreement with Sechenov University to create two innovative drugs for the treatment of diabetes mellitus is an important event for the entire pharmaceutical industry in Russia. We are convinced that new drugs will bring significant improvements in the treatment of serious socially significant diseases, providing Russian patients with access to advanced and effective methods of therapy. This is an important contribution to the health of the nation and strengthening our national potential».